Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
11/2003
11/27/2003WO2003097845A1 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
11/27/2003WO2003097806A2 Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/27/2003WO2003097665A2 Mid 241 receptor, a novel g-protein coupled receptor
11/27/2003WO2003097659A1 6-11 bicyclic ketolide derivatives
11/27/2003WO2003097658A2 Compounds and methods for inhibiting selectin-mediated function
11/27/2003WO2003097649A2 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
11/27/2003WO2003097648A1 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the prepartion thereof
11/27/2003WO2003097639A1 Benzoxazine and benzoxazinone substituted triazoles
11/27/2003WO2003097638A1 (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofurylcarbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
11/27/2003WO2003097636A1 Novel compounds and their use
11/27/2003WO2003097633A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics
11/27/2003WO2003097613A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors
11/27/2003WO2003097612A1 Substituted 2-phenyl-3(2h)-pyridazinones
11/27/2003WO2003097608A2 Opioid and opioid-like compounds and uses thereof
11/27/2003WO2003097606A1 New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole
11/27/2003WO2003097601A1 Cyanoguanidine prodrugs
11/27/2003WO2003097597A2 Indole derivatives and the use thereof as cb2 receptor ligands
11/27/2003WO2003097591A1 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
11/27/2003WO2003097586A1 Aminotetralin-derived urea modulators of vanilloid vr1 receptor
11/27/2003WO2003097573A1 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
11/27/2003WO2003097104A1 Treatment and prevention of tissue damage
11/27/2003WO2003097082A2 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
11/27/2003WO2003097073A1 Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
11/27/2003WO2003097071A1 Hormone replacement therapy using a combination of conjugated estrogens and trimegestone
11/27/2003WO2003097062A1 Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
11/27/2003WO2003097052A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
11/27/2003WO2003097051A2 Use of compounds that are effective as selective opiate receptor modulators
11/27/2003WO2003097047A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
11/27/2003WO2003097041A1 Annelated pyrrole compounds as proton pump inhibitors for treating ulcer
11/27/2003WO2003097040A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
11/27/2003WO2003097034A1 TGF-α EXPRESSION INHIBITORS
11/27/2003WO2003097029A1 Methods of treating gastrointestinal and genitourinary pain disorders using vinlafaxin and derivatives
11/27/2003WO2003097027A1 OIL-IN-WATER EMULSION OF l-MENTHOL
11/27/2003WO2003097026A1 Smooth muscle peristole inhibitor
11/27/2003WO2003096989A2 Anti tubercular drug: compositions and methods
11/27/2003WO2003096977A2 Methods of treating hepatitis
11/27/2003WO2003096808A1 Prevention or treatment of abnormal lipoprotein, cholestasis and atherosclerosis
11/27/2003WO2003078568A3 Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
11/27/2003WO2003067209A3 Ligands to enhance cellular uptake of biomolecules
11/27/2003WO2003066594A3 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
11/27/2003WO2003065983A3 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
11/27/2003WO2003064622A3 Aggrecanase molecules
11/27/2003WO2003047417A3 Ep4 receptor agonist, compositions and methods thereof
11/27/2003WO2003039446A3 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
11/27/2003WO2003032965A3 Use of ace inhibitors for reducing type 2 diabetes in high risk patients
11/27/2003WO2003032964A3 Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
11/27/2003WO2003031651A3 Method of determining susceptibility to inflammatory bowel disease
11/27/2003WO2003022852A3 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
11/27/2003WO2003020759A3 A caspase- 8 binding protein, its preparation and use
11/27/2003WO2003008443A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
11/27/2003WO2003006620A3 Linear and cyclic melanocortin receptor-specific peptides
11/27/2003WO2003005971A3 Tetracycline compounds having target therapeutic activities
11/27/2003WO2002100813A3 Modulators of peroxisome proliferator activated receptors
11/27/2003WO2002092004A8 Use of hmg fragment as anti-inflammatory agents
11/27/2003WO2002086156A3 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
11/27/2003WO2002086113A3 Enzyme and snp marker for disease
11/27/2003WO2002085940A3 New polynucleotides and polypeptides of the erythropoietin gene
11/27/2003WO2002079170A3 Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing them
11/27/2003WO2002072095A3 Tiotropium salts for treating inflammatory diseases
11/27/2003WO2002057242A3 Urea derivatives as integrin alpha 4 antagonists
11/27/2003WO2000050046A8 Stabilized oral pharmaceutical composition containing iodide and iodate and method
11/27/2003US20030220468 Modified forms of pharmacologically active agents and uses therefor
11/27/2003US20030220397 Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
11/27/2003US20030220389 Tertiary amines such as 2-dimethylaminomethyl-1-(3-methoxy-phenyl)-6-methylcyclohexanol, used as analgesics
11/27/2003US20030220375 N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
11/27/2003US20030220372 Imidazole compounds as anti-inflammatory and analgesic agents
11/27/2003US20030220367 Administering a therapeutical carbamate derivative to a patient as prostaglandin IP (12 or PGI2) antagonists
11/27/2003US20030220364 New compounds
11/27/2003US20030220353 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/27/2003US20030220347 Compounds and methods for treatment of asthma, allergy and inflammatory disorders
11/27/2003US20030220341 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
11/27/2003US20030220330 Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
11/27/2003US20030220325 Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling
11/27/2003US20030220322 Substituted 3,4-dihydro-pyrimido[1,2a]pyrimidines and 3,4-dihydro-pyrazino[1,2a]pyrimidines, and methods for their preparation and use
11/27/2003US20030220319 Such as 1-(4,5-dihydro-1H-imidazol-2-ylmethyl)-3-methanesulfonyl-2-methyl-1H-indole for preventing/treating disorders modulated by alpha-1A/L adrenoceptors such as urinary incontinence and sexual disorders
11/27/2003US20030220318 New phenylalanine derivatives
11/27/2003US20030220303 GABAB Receptor Agonists; used to treat gastrointestinal disorders, especially GERD
11/27/2003US20030220299 Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
11/27/2003US20030220297 Phosphorus-containing compounds and uses thereof
11/27/2003US20030220277 Methylation of plasmid vectors
11/27/2003US20030220271 Motilide compounds
11/27/2003US20030220268 New phenylalanine derivatives
11/27/2003US20030220243 A 37 amino acid peptide that is secreted by the L-cells of the intestine in response to food ingestion, because of their ability to stimulate insulin secretion, can be used for the treatment of diabetes, obesity and releated conditions
11/27/2003US20030220228 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/27/2003US20030219875 Albumin fusion proteins
11/27/2003US20030219864 Novel variants of RANKL protein
11/27/2003US20030219497 Methods of treating ileus
11/27/2003US20030219439 Genetic enginieered mixtures of complementary determining regions(CDR) antigens used for analyzing neutralizing epitopes and for prophylaxis of allergies and respiratory system disorders
11/27/2003US20030219438 Human antibodies that bind human TNFalpha
11/27/2003US20030219437 Administering antibodies used as antagonists to CD antigen ligands on the cells, for prophylaxis of cardiovascular, gastrointestinal or urogenital disorders
11/27/2003US20030219413 Method for overexpression of zwitterionic polysaccharides
11/27/2003CA2812019A1 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
11/27/2003CA2794297A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of amyloidosis
11/27/2003CA2794060A1 Methods and compositions using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of multiple myeloma
11/27/2003CA2752140A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
11/27/2003CA2752127A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of hepatocellular carcinoma
11/27/2003CA2752124A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
11/27/2003CA2752122A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of ovarian cancer
11/27/2003CA2727830A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2727824A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of solid tumors
1 ... 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 ... 1258